Unknown

Dataset Information

0

"Real life" use of raltegravir during pregnancy in France: The Coferal-IMEA048 cohort study.


ABSTRACT: INTRODUCTION:Limited "real life" data on raltegravir (RAL) use during pregnancy are available. Thus, we aimed at describing effectiveness and safety of RAL-based combined antiretroviral therapy (cART) in this setting. METHODS:HIV-1-infected women receiving RAL during pregnancy between 2008 and 2014 in ten French centers were retrospectively analysed for: (1) proportion of women receiving RAL anytime during pregnancy who achieved a plasma HIV-RNA (pVL) < 50 copies/mL at delivery, and (2) description of demographics, immuno-virological parameters and safety in women and new-borns. RESULTS:We included 94 women (median age, 33 years) of which 85% originated from Sub-Saharan Africa and 16% did not have regular health insurance coverage. Sixteen women were cART-naïve (median HIV diagnosis at 30 weeks of gestation), whereas 78 were already on cART before pregnancy (40% with pVL < 50 copies/mL). RAL was initiated before pregnancy (n = 33), during the second trimester (n = 11) and the third trimester of pregnancy (n = 50). No RAL discontinuations due to adverse events were observed. Overall, at the time of delivery, pVL was < 50 copies/mL in 70% and < 400 copies/mL in 84% of women. Specifically, pVL at delivery was < 50 copies/mL in 82%, 55% and 56% of cases when RAL was started before pregnancy, during the second or third trimester of pregnancy, respectively. Median term was 38 weeks of gestation, no defect was reported and all new-borns were HIV non-infected at Month 6. CONCLUSIONS:RAL appears safe and effective in this "real-life" study. No defect and no HIV transmission was reported in new-borns.

SUBMITTER: Gantner P 

PROVIDER: S-EPMC6481866 | biostudies-other | 2019

REPOSITORIES: biostudies-other

altmetric image

Publications


<h4>Introduction</h4>Limited "real life" data on raltegravir (RAL) use during pregnancy are available. Thus, we aimed at describing effectiveness and safety of RAL-based combined antiretroviral therapy (cART) in this setting.<h4>Methods</h4>HIV-1-infected women receiving RAL during pregnancy between 2008 and 2014 in ten French centers were retrospectively analysed for: (1) proportion of women receiving RAL anytime during pregnancy who achieved a plasma HIV-RNA (pVL) < 50 copies/mL at delivery, a  ...[more]

Similar Datasets

| S-EPMC4213295 | biostudies-literature
| S-EPMC5498419 | biostudies-literature
| S-EPMC8638412 | biostudies-literature
| S-EPMC10036711 | biostudies-literature
2024-07-26 | GSE272645 | GEO
| S-EPMC6046485 | biostudies-literature
| S-EPMC6687733 | biostudies-literature
| S-EPMC6636733 | biostudies-literature
| S-EPMC8653094 | biostudies-literature
| S-EPMC5594425 | biostudies-literature